19 completed, 3 terminated, 3 unknown, 1 enrolling by invitation. 26 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 26 | Completed 19, Terminated 3, Unknown 3, Enrolling by invitation 1 |
Follow insulin degludec: new trials by email Literature Review of insulin degludec trials Research Report on insulin degludec
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Comparing Degu Insulin Liraglutide Injection With Premixed Insulin on the Prognosis of Diabetes Mellitus Degludec insulin - Type 2 Diabetic Patients | Phase 4 | Enrolling by invitation | Beijing Tsinghua Chang Gung Hospital | 170 | 2024-05-20 | 2025-04-13 |
| Comparing the Safety and Efficacy of Insulin GLARGINE and DEGLUDEC in Glucocorticoid Induced HYPERGLYCEMIA in Hospitalized Patients". Degludec insulin, Glargine insulin - Glucocorticoid Induced Hyperglycemia | Phase 4 | Completed | Max Healthcare Insititute Limited | 79 | 2023-09-01 | 2026-05-20 |
| INHALE-3: Afrezza® Combined With Insulin Degludec Versus Usual Care in Adults With Type 1 Diabetes Afrezza, insulin degludec, Rapid-acting Insulin Analog - Diabetes Mellitus, Type 1 | Phase 4 | Completed | Mannkind Corporation | 141 | 2023-07-07 | 2024-08-09 |
| Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment Insulin glargine 300 U/mL, Insulin degludec 100 U/mL - Type 2 Diabetes Mellitus, Renal Impairment | Phase 4 | Terminated | Sanofi | 62 | 2022-12-05 | 2025-09-08 |
| Afrezza With Basal Combination (ABC): Afrezza® Combined With AID Pump or Insulin Degludec in Adults With Type 1 Diabetes Afrezza (insulin human) Inhalation Powder, insulin degludec, Continuous Subcutaneous Insulin Infusion (CSII) pump with Automatic Insulin Delivery (AID) - Type 1 Diabetes | Phase 4 | Completed | Mannkind Corporation | 33 | 2022-03-31 | 2025-04-08 |
| Basal Plus GLP1-ra on Glycemic Variability in CKD Dulaglutide, Insulin Degludec, Continuous glucose monitor - Diabetes Mellitus, Diabetic Kidney Disease | Phase 4 | Completed | Elaine Chow | 95 | 2022-01-28 | 2024-12-03 |
| Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients Insulin Degludec / Liraglutide Injectable Product, Insulin Glargine - Diabetes Mellitus, Type 2 | Phase 4 | Completed | University of Palermo | 100 | 2021-04-01 | 2023-12-15 |
| Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D Semaglutide, Insulin Degludec, Insulin aspart - Type 2 Diabetes | Phase 4 | Completed | The Cleveland Clinic | 60 | 2021-01-18 | 2025-02-18 |
| Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose Insulin Degludec, Insulin Glargine, Placebo - Type 1 Diabetes | Phase 4 | Completed | University of Washington | 59 | 2020-02-14 | 2024-02-28 |
| Comparison of Glucose Values and Variability Between TOUJEO and TRESIBA During Continuous Glucose Monitoring in Type 1 Diabetes Patients Insulin glargine, 300 U/ml, Insulin degludec, 100U/ml, Background therapy: Rapid acting insulin analogs - Type 1 Diabetes Mellitus | Phase 4 | Completed | Sanofi | 343 | 2019-10-09 | 2022-11-14 |
| Intermediate and Long Acting Insulin Young Children Type 1 Diabetes. Degludec, Glargine, NPH insulin - Type 1 Diabetes Mellitus With Hypoglycemia, type1diabetes | Phase 4 | Unknown | Ain Shams University | 60 | 2019-02-21 | 2021-02-16 |
| Insulin Glargine U300 vs Insulin Degludec U100 in Impact on the Glycaemic and Cardiovascular Factors Degludec, Glargine U300 - Diabetes Mellitus, Type 2 | Phase 4 | Completed | University of Split, School of Medicine | 25 | 2018-12-15 | 2020-12-31 |
| Comparison of Insulin Degludec With Insulin Glargine U100 for Adults With Type 1 Diabetes Crossing Multiple Time Zones. Insulin Degludec, Insulin Glargine, TRESIBA® FLEXTOUCH® - Diabetes Mellitus, Type 1 | Phase 4 | Completed | Sansum Diabetes Research Institute | 25 | 2018-11-16 | 2022-11-01 |
| A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO Study Insulin degludec, Insulin glargine - Diabetes Mellitus, Type 2 | Phase 4 | Completed | Novo Nordisk A/S | 498 | 2018-10-02 | 2021-01-12 |
| Flexible Insulin Therapy Untethered Insulin Regimen in Avidly Exercising Patients With Type 1 Diabetes: FIT Untethered Insulin Degludec - Type 1 Diabetes Mellitus | Phase 4 | Unknown | LMC Diabetes & Endocrinology Ltd. | 30 | 2018-05-15 | 2019-02-12 |
| Basal Insulin Glycemic ControL With DEglugec vs Aspart Via Pump Aspart - Type1 Diabetes Mellitus | Phase 4 | Completed | Mountain Diabetes and Endocrine Center | 59 | 2018-04-12 | 2021-02-24 |
| Randomised Open Label Study of Insulin Degludec Versus Insulin Glargine U100 in Ramadan Insulin Degludec U100, Insulin Glargine - Type2 Diabetes | Phase 4 | Terminated | Weill Cornell Medical College in Qatar | 273 | 2018-01-07 | 2020-06-09 |
| Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes Degludec, Glargine, Aspart - Type 2 Diabetes | Phase 4 | Completed | Emory University | 180 | 2018-01-02 | 2022-03-31 |
| Basal-bolus Insulin Therapy Versus Standard Therapy for the Inpatient Management of Type 2 Diabetes: the IDA2 Study Insulin Degludec 100 UNT/ML [Tresiba] - Type 2 Diabetes Mellitus | Phase 4 | Unknown | Merete Bechmann Christensen | 100 | 2017-04-01 | 2017-08-09 |
| Impact on the Oxidative Stress of the Different Analogues of Insulin in People With Type 1 Diabetes. (Ineox Study) Toujeo SoloStar, Tresiba, Humalog Kwikpen - Type 1 Diabetes Mellitus | Phase 4 | Completed | Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud | 300 | 2017-01-20 | 2021-12-06 |
Showing 20 of 26. Sign in to see all of them.
Diabetes Mellitus, Type 2 (13) · Diabetes Mellitus, Type 1 (8) · Diabetes Mellitus (4) · Insulin Resistance (4) · Autoimmune Diseases (1) · Diabetic Nephropathies (1) · Endocrine System Diseases (1) · Glucose Metabolism Disorders (1) · Hypoglycemia (1) · Metabolic Diseases (1) · Motor Activity (1) · Renal Insufficiency (1) · Respiratory Aspiration (1)
Sanofi (5) · Mannkind Corporation (2) · Ain Shams University (1) · Beijing Tsinghua Chang Gung Hospital (1) · Elaine Chow (1) · Emory University (1) · Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (1) · LMC Diabetes & Endocrinology Ltd. (1) · Laniado Hospital (1) · Max Healthcare Insititute Limited (1) · Merete Bechmann Christensen (1) · Mountain Diabetes and Endocrine Center (1) · Nordsjaellands Hospital (1) · Novo Nordisk A/S (1) · Sansum Diabetes Research Institute (1)
United States (11) · United Kingdom (4) · Brazil (3) · Denmark (3) · France (3) · Hungary (3) · Italy (3) · Romania (3) · Spain (3) · Canada (2) · Croatia (2) · Czechia (2) · Germany (2) · Greece (2) · Ireland (2)
Kevin Kaiserman, MD (2) · Antonino Tuttolomondo, Professor (1) · Arthi Thirumalai, MD (1) · David Kerr, M.D. (1) · Guillermo Umpierrez, MD (1) · Irl B. Hirsch, MD (1) · Kevin Pantalone, DO (1) · Kirsten B Norgaard, DMSC (1) · Safinaz El Habashy (1) · Stephen Atkin, MD (1) · Ulrik Pedersen-Bjergaard, MD, DMSc (1)
PMID 31865758, PMID 33166419, PMID 20091571, PMID 22594461, PMID 25998289, PMID 27629148, PMID 28672316, PMID 30104294, PMID 31337371, PMID 32100192, PMID 32445738, PMID 33926446, PMID 34322967, PMID 34490700, PMID 34716211, PMID 35467938, PMID 35802405, PMID 36905485, PMID 37671755, PMID 38418413, PMID 39532398, PMID 40531276
2015 (3), 2017 (2)